The SSRI paroxetine (Paxil) showed the greatest overall reduction in hot flashes (40.6% at 10 mg and 51.7% at 20 mg; P = .0006 and P = .002, respectively) across both classes when compared with...

2024年5月3日 · Introduction: Selective serotonin reuptake inhibitors (SSRIs) antidepressants and non-SSRI antidepressants have been shown to decrease the frequency and strength of hot flashes, with few side effects. SSRI antidepressants include: Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Paroxetine (Paxil) Sertraline (Zoloft)

Hot flashes are the most commonly reported vasomotor symptom during the peri- and early post-menopausal period. To systematically review, appraise and summarize the evidence of the impact of different SSRIs on peri-menopausal hot flashes in healthy ...

In this study, escitolapram (Lexapro) was the most effective SSRI for reducing the daily frequency of hot flashes. Participants in the SSRI group also reported a reduction in severity of residual hot flashes compared to placebo.

Objectives: To systematically review, appraise and summarize the evidence of the impact of different SSRIs on peri-menopausal hot flashes in healthy women in randomized, controlled trials.

2022年6月28日 · How SSRIs May Reduce Hot Flashes. Certain antidepressants can treat hot flashes caused by menopause. They may be helpful if you’re unable to use hormone replacement therapy (HRT), or if you prefer a non-hormonal option.

According to the literature, SSRIs and SNRIs are more widely used to treat menopausal hot flashes than hormone replacement therapy. This systematic review will help psychiatrists to identify the most effective therapeutic options for the treatment of menopausal HF.

Antidepressants — Antidepressant medications are recommended as a first-line treatment for hot flashes in people who cannot take estrogen. SSRIs – The selective serotonin receptor inhibitors (SSRIs) are the class of antidepressants used most commonly for treating hot flashes.

The SSRIs and SNRIs can reduce hot flashes by 65% and begin working within the first week. Patient response is variable and if one drug does not improve hot flashes, another can be tried after a 1- to 2-week drug trial.

2013年7月26日 · Hot flashes are the most commonly reported vasomotor symptom during the peri- and early post-menopausal period. To systematically review, appraise and summarize the evidence of the impact of different SSRIs on peri-menopausal hot flashes in healthy women in randomized, controlled trials.